A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

PHASE2RecruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

June 17, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

October 31, 2027

Conditions
Atopic DermatitisAtopic Dermatitis EczemaEczema
Interventions
DRUG

IMG-007

Participants will receive IMG-007 subcutaneously.

DRUG

Placebo

Participants will receive a placebo subcutaneously.

Trial Locations (18)

11415

RECRUITING

Forest Hills Dermatology Group, Kew Gardens

11797

RECRUITING

Vitality Clinical Trials LLC, Woodbury

29621

RECRUITING

Palmetto Clinical Trial Services, LLC, Anderson

33609

RECRUITING

Palm Harbor Dermatology PA d/b/a TrueBlue Clinical Research, Tampa

43213

RECRUITING

ClinOhio Research Services LLC., Columbus

44124

RECRUITING

Apex Clinical Research Center, Mayfield Heights

58103

RECRUITING

Red River Research Partners, LLC, Fargo

60008

RECRUITING

Arlington Dermatology, Rolling Meadows

76092

RECRUITING

Stryde Research-Epiphany Dermatology, Southlake

93534

RECRUITING

Antelope Valley Clinical Trials, Lancaster

97210

RECRUITING

Oregon Dermatology and Research Center, Portland

698168

RECRUITING

Dermatology of Seattle & Bellevue, Burien

V3R 6A7

RECRUITING

Dr. Chin-ho-Hong Medical Inc., Surrey

P3C 1X8

RECRUITING

Sudbury Skin Clinique, Greater Sudbury

L4Y 4C5

RECRUITING

DermEdge Research, Mississauga

P1B 3Z7

RECRUITING

North Bay Dermatology Centre, North Bay

H2X 2V1

RECRUITING

Innovaderm Research Inc., Montreal

S7K 2C1

RECRUITING

Skinsense Medical Research, Saskatoon

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Inmagene LLC

INDUSTRY

NCT07037901 - A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter